| 0.6987 0.094 (15.58%) | 05-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.81 |
1-year : | 0.95 |
| Resists | First : | 0.69 |
Second : | 0.81 |
| Pivot price | 0.49 |
|||
| Supports | First : | 0.51 |
Second : | 0.4 |
| MAs | MA(5) : | 0.55 |
MA(20) : | 0.49 |
| MA(100) : | 0.53 |
MA(250) : | 0.72  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 97.7 |
D(3) : | 89.6 |
| RSI | RSI(14): 76.1 |
|||
| 52-week | High : | 1.14 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LCTX ] has closed above the upper band by 26.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 90.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.69 - 0.7 | 0.7 - 0.7 |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Thu, 15 May 2025
Lineage Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Wed, 14 May 2025
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Wed, 14 May 2025
Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Tue, 13 May 2025
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Thu, 01 May 2025
Lineage Cell Therapeutics announces cGMP production success - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 189 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 50.3 (%) |
| Shares Short | 15,820 (K) |
| Shares Short P.Month | 14,560 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | 0 % |
| Operating Margin | -416.7 % |
| Return on Assets (ttm) | -12.9 % |
| Return on Equity (ttm) | -35.1 % |
| Qtrly Rev. Growth | -56.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -5.38 |
| PEG Ratio | 0 |
| Price to Book value | 1.94 |
| Price to Sales | 21.31 |
| Price to Cash Flow | -6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|